Multiple diseases: Should we treat all?;Polypathologies: Faut-il tout traiter?

Revue Medicale Suisse

Volumn 1, Issue 14, 2005, Pages 941-947

  Biollaz, Jérôme ^a   Buclin, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ELETRIPTAN; ENALAPRIL; METOCLOPRAMIDE; SERTRALINE; SIMVASTATIN;

CLINICAL STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HUMAN; INDIVIDUALIZATION; PATIENT MONITORING; PRESCRIPTION; QUESTIONNAIRE; REVIEW; TREATMENT INDICATION; POLYPHARMACY; STANDARD;

HUMANS; POLYPHARMACY; PRESCRIPTIONS, DRUG;

EID: 33644663395     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Chobanian AV Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report JAMA 2003;289:2560-71
2. Masoudi FA, Krumholz HM. Polypharmacy and comorbidity in heart failure. BMJ 2003;327:513-4.
3. Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004;350:277-80.
4. Garber AJ. Benefits of combination therapy of insulin and oral hypoglycemic agents. Arch Intern Med 2003;163:1781-2.
5. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004;291:317-24.
6. Pitt B, Zanad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
7. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
8. Dalal H, Evans PH, Campbell JL. Recent developments in secondary prevention and cardiac rehabilitation after acute myocardial infarction. BMJ 2004;328:693-7.
9. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
10. Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: Can population impact measures help? BMC Public Health 2003;3:7.
11. Marshall T. Coronary heart disease prevention: Insights from modelling incremental cost effectiveness. BMJ 2003;327:1264-7.
12. Goldberg RM, Mabbe J, Chan L, Wong S. Drug-drug and drug-disease interactions In the ED: Analysis of a high risk population. Am J Emerg Med 1996;14:447-50.
13. Mannesse CK, Derks FHM, De Ridder MAJ, Man in't Veld AJ, Van der Cammen TJM. Contribution of adverse drug reactions to hospital admission of older patients. Age Aging 2000;29:35-9.
14. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001;15:1369-77.
15. Murray MD, Kroenke K. Polypharmacy and medication adherence: Small steps on a long road. J Intern Med 2001;16:137-9.
16. Simon P. Prioritization of medical problems to improve adherence. Clin Pharmacol Ther 2002;71:211-3.
17. Gill TM, Feinstein AR. A critical appraisal of the quality-of-life measurements. JAMA 1994;272:619-26.
18. Chutka DS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin Proc 2004;79:122-39.
19. Thiemann DR, Schulman SP. Thrombolytics in elderly patients: A triumph of hope over experience? CMAJ 2001;164:1301-3.
20. Redelmeier DA, Siew HT, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998;338:1516-20.
21. Sloane PD, Gruber-Baldini AL, Zimmerman S, et al. Medication undertreatment in assisted living settings. Arch Intern Med 2004;164:2031-7.
22. Shoudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-7.
23. Nelson EC, Mohr JJ, Batalden PB, et al. Improving health care. Part I. The clinical value compass. J Qual Improv 1996;22:243-58.
24. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: The prescribing cascade. BMJ 1997;315:1096-9.
25. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients. JAMA 1998;279:1200-5.
26. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
27. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.